RHUMBLINE ADVISERS

Position in ELVN — Enliven Therapeutics, Inc.

CIK 1115418 BOSTON, MA

Position in ELVN

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$2,904,980

+$937,611 QoQ

Shares Held

57,241

+14.1% QoQ

Ownership

0.078%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#94

of 210 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 26% Shared 0% None 74%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,404,724,682 across 329 Biotechnology names. ELVN ranks #79 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	396,380	$196,893,837
2	REGN	Regeneron Pharmaceuticals, Inc.	157,794	$98,390,870
3	MRNA	Moderna, Inc.	809,853	$56,714,005
4	ALNY	Alnylam Pharmaceuticals, Inc.	165,579	$49,844,246
5	INCY	Incyte Corp	428,533	$48,578,500
6	RVMD	Revolution Medicines, Inc.	226,008	$42,326,778
7	ROIV	Roivant Sciences Ltd.	1,178,789	$41,717,342
8	JAZZ	Jazz Pharmaceuticals plc	163,018	$39,282,447

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,904,980	57,241	+14.1%	Shares	Sole	2026-08-12
2026-03-31	$1,967,369	50,188	-0.6%	Shares	Sole	2026-05-12
2025-12-31	$777,838	50,509	-16.0%	Shares	Sole	2026-02-13
2025-09-30	$1,231,475	60,160	+19.6%	Shares	Sole	2025-11-06
2025-06-30	$1,008,616	50,280	-4.2%	Shares	Sole	2025-08-12
2025-03-31	$1,033,239	52,502	+4.9%	Shares	Sole	2025-05-29
2024-12-31	$1,125,810	50,036	+0.3%	Shares	Sole	2025-05-29
2024-09-30	$1,273,577	49,866	+0.5%	Shares	Sole	2024-11-12
2024-06-30	$1,159,782	49,627	+29.9%	Shares	Sole	2024-08-01
2024-03-31	$672,061	38,207	+2.3%	Shares	Sole	2024-05-09
2023-12-31	$516,827	37,343	+8.7%	Shares	Sole	2024-02-08
2023-09-30	$469,398	34,363	-1.2%	Shares	Sole	2023-11-09
2023-06-30	$710,186	34,796	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.